Sanofi’s Dupilumab, Chugai’s PD-L1 Inhibitor and More Up for MHLW Panel Review on Nov. 6

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) will review on November 6 whether to recommend approval for Sanofi’s blockbuster hopeful dupilumab and Chugai Pharmaceutical’s anti-PD-L1 antibody atezolizumab. The Pharmaceutical Affairs and Food Sanitation Council’s...read more